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Currently, nutraceuticals do not have a specific definition distinct from those of other food-derived categories, such as food
supplements, herbal products, pre- and probiotics, functional foods, and fortified foods. Many studies have led to an under-
standing of the potential mechanisms of action of pharmaceutically active components contained in food that may improve
health and reduce the risk of pathological conditions while enhancing overall well-being. Nevertheless, there is a lack of clear
information and, often, the claimed health benefits may not be properly substantiated by safety and efficacy information or
in vitro and in vivo data, which can induce false expectations and miss the target for a product to be effective, as claimed. An of-
ficially shared and accepted definition of nutraceuticals is still missing, as nutraceuticals are mostly referred to as pharma-foods, a
powerful toolbox to be used beyond the diet but before the drugs to prevent and treat pathological conditions, such as in subjects
who may not yet be eligible for conventional pharmaceutical therapy. Hence, it is of utmost importance to have a proper and
unequivocal definition of nutraceuticals and shared regulations. It also seems wise to assess the safety, mechanism of action and
efficacy of nutraceuticals with clinical data. A growing demand exists for nutraceuticals, which seem to reside in the grey area
between pharmaceuticals and food. Nonetheless, given specific legislation from different countries, nutraceuticals are
experiencing challenges with safety and health claim substantiation.
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Introduction
There is a growing overlap between conventional food
(including beverages) and food supplements, including
energy bars and teas or liquids. This overlap becomes even
wider when we consider functional foods and nutraceuticals.
What could be considered a functional food under a given set
of circumstances may be named a dietary supplement,
medical food, food for special dietary use or nutraceutical
under different circumstances, depending on its ingredients
(active components) and the claims reported on its label [1].
While the definition of a food supplement is quite clear
and understandable (see Table 1), the definition of a
nutraceutical is still in the grey area between food, food
supplements and pharmaceuticals. The term nutraceutical, a
syncretic neologism of the words nutrient and pharmaceutical,
was originally coined by Stephen DeFelice, who defined
nutraceuticals as “food or part of a food that provides medical
or health benefits, including the prevention and/or treat-
ment of a disease” [2]. This concept has been proposed as
a modern approach to food science, and the area of possi-
ble use has been defined as beyond the diet, but before the
drugs [3, 4]. Notwithstanding this concept, the definition
of nutraceuticals and a legitimate assessment of their
potential in medicine are still contradictory and far from
being shared and accepted worldwide [5].
The nutraceutical definition often overlaps with the
accepted definition of food supplements [6, 7], and the
rationale behind the use of these products is becoming
more and more important in their distinction.
Nutraceuticals are continuously developed and have
quickly spread worldwide [8]. Existing contradictory infor-
mation in the field is generating confusion about the possible
effective use of these products, which are available on the
market and in pharmacies. Food supplements, as per their
micronutrient content, can be used to improve the health
of individuals in need. In general, many of the health claims
that are currently associated with food supplements, pro- and
prebiotics, herbal products, and functional foods may not
properly be substantiated by scientific data on their safety,
efficacy and effect on health and/or pathological conditions.
The claims are mainly unsubstantiated due to a lack of
studies on possible mechanisms of action and a lack of
in vivo research confirming the claimed beneficial health
effects on specific pathological conditions. Another key
aspect is related to the data reported in the literature, which
mainly comes from in vitro studies focused on single food
constituents (micronutrients); these studies are based on the
assumption that micronutrients can be considered safe (or
generally recognized as so) because they are derived from
commonly used food or food components [8, 9]. Safety is of
utmost importance, as there is also the possibility of
contaminants of inorganic and organic origins in these
products [10, 11]. Moreover, the ingredients themselves may
cause health problems, and proper information on possible
unwanted side effects should be provided on the label. From
our point of view, it is imperative to have more information
on safety and efficacy based on clinical studies rather than
only in vitro studies, and it is also important to reach a better
understanding of the mechanism of action and bioavailabil-
ity of these products. The first step in assessing the action of
nutraceuticals is to distinguish them from the other food-
derived products, particularly food supplements, which are
not always included in daily dietary habits in the presence of
a specific need [12].
This exercise may require: (i) appropriate target identifica-
tion; (ii) safety assessment; (iii) a clear understanding of the
mechanism of action; (iv) efficacy assessment substantiated
by clinical studies; (v) an evaluation of possible unwanted
side effects; and (vi) an evaluation of possible interactions
with other products (e.g. food, food supplements and drugs).
We think that a different approach for nutraceutical concept
assessment, use and definition is needed, and the existing
assessment methodology for pharmaceutical products may
be considered as a starting point.
Resolving the discrepancies between the different
accepted definitions of nutraceuticals and their regulatory
aspects will be a significant challenge. An outline of the lack
of shared regulations regarding nutraceuticals as pharma-
foods is needed [13]; nutraceuticals are considered to be in
the grey area after diet, but before drugs. Therefore, it is
important to clearly identify their specificity in view of their
possible use and utility in the pharmaceutical arena.
State of the art and future trends
The first step in food regulation in Europe was established in
1997 with the Green Paper on Food Law, and it was followed
by the White Paper on Food Safety in 2000, which outlined
the need for new and improved legislation in the field [14].
These papers led to the General Food Law Regulation [Regula-
tion (EC) No. 178/2002 of the European Parliament and of
the Council 2002], which established the principle and
foresaw the creation of an independent organization called
the European Food Safety Authority (EFSA) with the specific
task of giving scientific advice based upon scientific
assessment of the beneficial health effects and associated risks
related to food intake [15].
The EFSA mission also includes food supplements,
whereas the responsibility for risk management and commu-
nication was taken on by the European Commission and
Parliament. The risk assessment and risk evaluation can also
be included as a part of the EFSA mandate if it follows a
specific request made by the European Commission and
Parliament from a European Member State or stakeholder.
This step should then be followed by specific action from
local national authorities, who take the suggestions on board
and propose appropriate legislation and regulation in the
field. The mission of the EFSA is to “provide the basis for the
assurance of a high level of protection of human health and
consumer interest in relation to food, considering the
diversity in the supply of food, including traditional
products, while ensuring the effective functioning of the
internal market. It establishes common principles and
responsibilities, the means to provide a strong science base,
efficient organizational arrangements and procedures to un-
derpin decision-making in matters of food and feed safety.”
This statement applies to all foodstuffs, and these general
principles also cover foods with added functional properties
(e.g. functional foods, food supplements, herbal products,
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Table 1
Some definitions for food-derived products
Food supplement (United States
Government Office, 1994)
A product (other than tobacco) in the form of a
capsule, powder, softgel or gelcap intended to
supplement the diet to enhance health that
bears or contains one or more of the
following dietary ingredients: a vitamin,
mineral, amino acid, or other botanical
or dietary substance.
United States Food and Drug Administration
(FDA). Dietary Supplement Health and Education
Act (DSHEA). U.S. Department of Health and
Human Services. 1994. United States. Public
Law 103–417, available at FDA Website:
http://www.fda.gov. [42]
Food supplement (EU, 2002) Food product whose purpose is to
supplement the normal diet and which
consists of a concentrated source of nutrients
or other substances with nutritional effects
or physiological, single or in combination,
marketed in dosed formulations, such as capsules,
tablets, tablets or pills, designed to be taken
in small individual quantities measured.
EU Directive 2002/46/EC [17]
Phytochemical (Bloch and
Thomson, 1995)
Substances found in edible fruit and vegetables
that can be ingested daily (in quantities of grams)
by humans and that exhibit a potential to
favourably modulate human metabolism to
prevent cancer and other diseases (isoflavones,
resveratrol, garlic allyl sulphides, tomato
lycopene, onion quercetin etc.).
Bloch A, Thomson CA. Position of The
American Dietetic Association (phytochemicals
and functional foods). J Am Diet Assoc
1995; 95: 493–496. [74]
Nutraceuticals (De Felice, 1995) Food or part of food that provides medical
or health benefits, including the prevention
and/or treatment of a disease.
DeFelice SL. The nutraceutical revolution:
its impact on food industry R&D. Trends
Food Sci Technol 1995; 6: 59–61. [2]
Nutraceuticals (Zeisel, 1999;
DSHEA, 1994)
A diet supplement that delivers a
concentrated form of a biologically
active component of food in a nonfood
matrix to enhance health.
Zeisel SH. Regulation of “Nutraceuticals”.
Science. 1999: 285; 1853–5. Food and
Drug Administration, FDA, Dietary
Supplement Health and Education
Act of 1994 (DSHEA), United States. [75]
Nutraceuticals (Brower, 1998) Any substance that is a food or a part
of a food and is able to induce medical
and health benefits, including the
prevention and treatment of disease.
Brower V. Nat Biotechnol 1998; 16: 728. [76]
Nutraceuticals (Merriam Webster
Dictionary, 2015)
A foodstuff (as a fortified food or
dietary supplement) that provides
health benefits in addition to
its basic nutritional.
Merriam-Webster Online Dictionary. 2015.
Merriam-Webster Inc., P.O. Box 281,
Springfield, MA 01102, United States. [77]
Nutraceuticals (ENA, 2016) Nutritional products that provide
health and medical benefits,
including the prevention
and treatment of disease.
European Nutraceutical Association (ENA).
2016. Science behind Nutraceuticals.
In E. N. Association (Ed.),
(Vol. 2016). 594 Basel, Switzerland. [78]
Functional food (Zeisel, 1999) Nutrient consumed as part of a
normal diet but delivering one or
more active ingredients
(that have physiological effects
and may enhance health)
within the food matrix.
Zeisel SH. Regulation of “Nutraceuticals”.
Science 1999: 285; 1853–5. Food and
Drug Administration, FDA, Dietary
Supplement Health and Education
Act of 1994 (DSHEA), United States. [79]
Functional food (Diplock et al., 1999) Product which is shown in a satisfactory
manner that, in addition to adequate
nutritional effects, induces beneficial
effects on one or more target functions
of the organism, significantly improving
the health status and welfare or
reducing the risk of disease.
Diplock A, Aggett P, Ashwell M, Bornet F,
Fern E, Roberfroid M. The European
Commission concerted action on
functional foods science in Europe
(FUFOSE). Scientific concepts of
functional foods in Europe.
Consensus document.
Br J Nutr 1999; 81: S1–S27. [80]
Functional food (Hardy, 2000) Any food or ingredient that has a positive
impact on an individual’s health,
physical performance, or state of
mind, in addition to its nutritive value.
Hardy G. Nutraceuticals and
functional foods: introduction
and meaning. Nutrition 2000; 16: 688–689. [81]
(continues)
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pre- and probiotics, and dietetic foods); hence, they could
also include nutraceuticals. The European Council Regula-
tion (EC) No. 178/2002 defines food or foodstuff as “any sub-
stance or product, whether processed, partially processed or
unprocessed, intended to be, or reasonably expected to be
ingested by humans” [15]. According to the abovementioned
definition, medicinal products cannot be considered food,
and this seems to suggest that one possible tool to decide
whether medicinal or food regulations apply to a specific
product may be identified in the medicinal regulation area.
Nonetheless, food derivatives with specific beneficial effects
on health, such as functional foods and nutraceuticals, can
be considered similar to medicinal products if their micronu-
trient content is considered. Medicinal products are defined
by Directive 2001/83/EC of the European Parliament, which
was amended by Directive 2004/27/EC of the Council [16].
This Directive, among others, addressed the requirements
and procedures for marketing authorization of medicinal
products for human use. Medicinal products are defined as
“any substance or combination of substances presented as
having properties for treating or preventing disease in human
beings, or any substance or combination of substances that
may be used in or administered to human beings either with
a view to restoring, correcting or modifying physiological
functions by exerting a pharmacological, immunological or
metabolic action, or to making a medical diagnosis”.
Section 2.2 of Directive 2004/27/EC clarifies that “In cases
of doubt, where, taking into account all its characteristics, a
product may fall within the definition of a ‘medicinal
product’ and within the definition of a product covered by
other Community legislation, the provisions of this Directive
shall apply” [16].
In our opinion, nutraceuticals require an appropriate
description and specific classification. Nevertheless, while
nutraceuticals should always have specific added health value
for the prevention or treatment of pathological conditions,
food supplements may not be required to have this character-
istic. Notwithstanding the differences existing between them
that were outlined previously, Article 2 of Directive 2002/46/
EC (Directive 2002/46/EC of the European Parliament and of
the Council 2002) defines only food supplements as “food-
stuffs, the purpose of which is to supplement the normal diet
and which are concentrated sources of nutrients or other
substances with a nutritional or physiological effect, alone
or in combination, marketed in dose form, namely, forms
such as capsules, pastilles, tablets, pills and other similar
forms, sachets of powder, ampoules of liquids, drop dispens-
ing bottles, and other similar forms of liquids and powders
designed to be taken in measured small unit quantities”,
without mentioning nutraceuticals [17].
Food supplements can contain substances with a physio-
logical effect other than nutritional value and so can
nutraceuticals, according to our view. A product must be
available in a concentrated form and should be taken in
the proper pharmaceutical form to fall under Directive
2002/46/EC.
Nutraceuticals can be marketed with same pharmaceuti-
cal form of food supplements. We instead propose a different
classification approach for these products to differentiate
them from food supplements [17]. The current European
Directive 2002/46/EC on food supplements mainly focuses
inter alia on vitamins and minerals as supplements and
foresees that maximum amounts of vitamins and minerals
must consider the upper safe levels established by scientific
risk assessment considering different consumer groups and
the intake of vitamins and minerals derived from other
dietary sources. For nutraceuticals, a different approach based
on beneficial health effects may be more appropriate consid-
ering the pharmacological effect of these food derivatives.
Prior to 2002, food supplements were subjected to national
regulations, which set the legislation framework and risk
assessment management. Regarding food supplements, the
European Responsible Nutrition Alliance (ERNA) suggested
a risk management model for determining maximum risk
levels for different nutrient intakes based on the population
safety index in 2004 [18]. In 2006, ERNA contributed to the
establishment of guidelines for nutrition and health claim
regulations, suggesting these guidelines as a tool for
companies to provide correct communication about the
many health benefits of vitamins, minerals, omega 3 fatty-
acids etc. [19].
The key aspect here is that food supplements and
nutraceuticals are both considered to be derived foodstuffs,
which means that, in many cases, the precautionary princi-
ple valid for food is applied to food supplements, and the
term nutraceutical is used for products available on the
market without proper assessment of their beneficial health
effects, except in cases specifically provided in the food
Table 1
(Continued)
Food for medical use (EU, 1999) Complete nutritional food with a formulation of
nutrients standards, which may constitute the sole
source nutrition for the person to whom it is addressed.
Or alternatively: complete nutritional food with a
formulation of nutrient adapted to a specific disease,
disorder or medical condition, which may constitute
the only source of nutrition for the person to whom
it is addressed. Or alternatively: nutritionally incomplete
food with a formulation standard nutrients or adapted
for a specific disease, disorder or medical condition,
which it is not suitable to be used as the
only source of nutrition.
EU Directive 1999/21/ EC. [82]
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supplement legislation itself. This arrangement does not
completely fix the issue of borderline definitions and classi-
fications between medicinal products, food supplements
and nutraceuticals [15].
It would hence be advisable that the European Commis-
sion or authorities in charge explore the possibility of
including nutraceuticals in their Directives or Regulations
by defining a new category that differentiates them from food
supplements and pharmaceuticals. This area is hence not
completely regulated in Europe nor in the USA. In particular,
no effective, shared regulatory system exists in the USA
regarding medical or health claims for nutraceuticals, even
though these products have entered mainstream science
and medicine and the consumer marketplace. This lack of
rules negatively influences the market for these products,
can generate confusion among consumers, and eventually,
can lead to possible misuse.
Nutraceuticals that demonstrate specific pharmacological
activities can claim beneficial health effects for pathological
conditions, and if they are considered vegetal supplements
(in cases of vegetal origin), they can be covered by legislation
for food supplements. This stipulation could, however, imply
the need to obtain authorization for a health claim from EFSA
in Europe, as a cause–effect relationship must be substanti-
ated by clinical data. An EFSA positive opinion would be nec-
essary to assess and recognize their potential use and hence
market the nutraceutical as a pharma-food, demonstrating
the large difference that exists between nutraceuticals and
food supplements. Regulation EC 1924/2006 on nutrition
and health claims made on food was issued to harmonize
the laws and different legislations among Member States to
guarantee safety and efficacy and to simultaneously protect
the internal market by providing proper, understandable
information to consumers [20]. In accordance with this
Regulation, any health or nutritional claims on food must
be approved from EFSA before marketing. Health claims are
generally related to nutritional profiles, the overall nutri-
tional composition of a foodstuff and the presence of nutri-
ents that have been scientifically recognized as having a
beneficial effect on health. National regulations often apply
in the absence of specific shared international rules concer-
ning recommendations or any endorsements by national
medical associations. This scheme outlines the need for a
supra national legal framework for claims and to provide
correct information to consumers. Nutraceuticals could be
effectively used to prevent and cure some illnesses, and
consequently their correct use and proper information on
claims substantiated by clinical data are of utmost impor-
tance. Nutraceuticals are generally reported to have good
safety profile with few unwanted side effects and high
bioavailability [21]. Their application area ranges from meta-
bolic syndrome and inflammation control to Alzheimer’s
disease [4, 22–27].
It must, however, be noted again that current European
legislation does not mention the term nutraceutical.
Nutraceuticals could be considered within the Foods for
Particular Nutritional Uses (PARNUTS) regulatory framework
(Directive 89/398/EEC 1989), which includes foods for
special medical purposes and food intended for particular
nutritional needs, once their safety and efficacy have been
properly assessed by in vitro and in vivo studies [28].
This aspect was first outlined in 2002 when the Founda-
tion for Innovation in Medicine guided by Stephen DeFelice
launched the idea to establish a shared regulatory framework
for nutraceuticals: the Nutraceutical Research and Education
Act, which envisioned the creation of a worldwide Nutraceu-
tical Commission specifically dedicated to the review and
approval of nutraceuticals and the development of
programmes stimulating clinical research in this field with
the aim of substantiating all health claims with clinical
data [29]. The realization of these actions and proper
worldwide availability of information could: (i) be beneficial
for individuals; (ii) be beneficial for research in this area; (iii)
help lower the cost of pharmacological treatment for the
National Health Systems by the adoption of prevention
mechanisms, including nutraceuticals in the daily diet
regimen; and (iv) realize a proactive approach towards
preventing, rather than curing, pathological conditions,
many of which may arise from improper diet and lifestyle
(e.g. metabolic syndrome). The simplest proactive preventive
approach could be recognized by changing lifestyle and
dietary habits and increasing physical activity, which have
been suggested by all national health disease prevention
plans. This outcome is, however, not always easy to achieve
in populations and remains to be completed.
Efficacy, together with safety, is to be considered of utmost
importance for nutraceuticals. European Council Regulation
(EC) No. 178/2002 on food introduced a precautionary
principle in the risk management process in 2002. Risk
analysis in authorization procedures and claims approval
may also be relevant for nutraceuticals, food supplements
and functional foods [15].
When possible harmful health effects are identified, but
not fully scientifically substantiated, the precautionary prin-
ciple protects the rights of individuals, industry and organiza-
tions with the necessity of reducing the risk of affecting the
health of humans, the environment, plants and animals.
The first step of safety assessment was established in 1997
with Regulation EC No. 258/97 of the European Parliament
and of the Council on novel foods and novel food ingredients
and was followed by European Council and Commission
Regulation EC No. 1852/2001 [30, 31].
Both recognized the need to have a safety assessment
through a shared procedure before placing food supplement
on the market. This procedure was demanded by the Member
States and is still far from being completed. In November
2015, Regulation EU 2015/2283 of the European Parliament
and of the Council on novel foods revised the rules to define
and place novel foods on the market within the European
Union, amending Regulation EU No. 1169/2011 of the
European Parliament and of the Council [32].
Novel foods appear, as per their definition, in Article 3,
and are described as “food consisting of, isolated from or pro-
duced from plants or their parts, except when the food has a
history of safe food use within the Union and is consisting
of, isolated from or produced from a plant or a variety of the
same species obtained by traditional propagating practices
which have been used for food production within the Union
before 15 May 1997, or nontraditional propagating practices
which have not been used for food production within the
Union before 15 May 1997, where those practices do not give
rise to significant changes in the composition or structure of
Nutraceutical regulatory framework
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the food affecting its nutritional value, metabolism or level of
undesirable substances”.
They are further defined as “food consisting of, isolated
from or produced from animals or their parts, except for
animals obtained by traditional breeding practices which
have been used for food production within the Union before
15May 1997 and the food from those animals has a history of
safe food use within the Union”.
The same Regulation also includes “food used exclusively in
food supplements within theUnion before 15May1997,where
it is intended to be used in foods other than food supplements
as defined in point (a) of Article 2 of Directive 2002/46/EC”.
The same consideration might be considered valid for foods
that have a “history of safe food use in a third country”, suggest-
ing that the safety of the food in question has been confirmed
from continued use for at least 25 years in the diet of a
significant number of people in at least one-third of the
country. Nutraceuticals are still notmentioned in the 2015 Reg-
ulation, notwithstanding their potential medicinal use to
prevent/cure some pathological conditions.
It may be feasible to apply current legislation for pharma-
ceuticals regarding efficacy, safety and health effect assess-
ment to nutraceuticals with the same restrictions. Another
possible approach could be to start by reconsidering Directive
1999/21/EC, which defines processed or formulated products
that are intended for the dietary management of individuals
with disrupted metabolism, or in special physiological
conditions, and must be prescribed by a medical doctor and
used under their supervision as PARNUTS [33]. PARNUTS
legislation could be adopted to draw a possible scheme for
nutraceutical validation with the aim of clearly
distinguishing them from food supplements and/or from
functional foods intended for particular nutritional or clini-
cal uses.
According to Directive 89/398/EEC, PARNUTS should
have a special composition for their claimed nutritional/
medical purposes and should be clearly different from food-
stuffs for dietary use [28]. These products should be addressed
to individuals who do not qualify for pharmacological
treatment and who could benefit from alternative treatment
given their proven efficacy. In this case, the possible target
population could be quite wide considering the growing
impact on health due to improper lifestyles, particularly
metabolic syndrome, which includes different pathological
health conditions, such as hypertriglyceridaemia, hyperten-
sion, hypercholesterolaemia, type II diabetes and obesity
[34, 35].
The need for a scientific rationale
The proper starting point for nutraceutical concept assess-
ment should begin with a sharp distinction between
nutraceuticals and food supplements and with the identifica-
tion of an appropriate epidemiological target. Food supple-
ments have been already defined as previously reported.
Regarding nutraceuticals, we propose the following
definition: (i) for food of vegetal origin, a nutraceutical is
the phytocomplex; and (ii) for food of animal origin, a nutra-
ceutical is the pool of secondary metabolites. Both are
concentrated and administered in the proper pharmaceutical
form. They are capable of providing beneficial health effects,
including the prevention and/or the treatment of a disease.
Table 1 collects some of the most common definitions of
these products together with other food-derived products.
Many of them belong to the food supplement category,
which also includes herbal products; these food supple-
ments are often miscategorized with nutraceuticals. All of
these productions, including pre- and probiotics, functional
foods, and herbal supplements, claim beneficial effects on
human health.
Food supplements are often confused with functional
food, which, as per their definition, are food-derived prod-
ucts (or food with the addition of one or more active com-
pounds) that are included as part of a normal diet with the
aim of obtaining beneficial health effects. These supple-
ments and functional foods can compensate and/or can
have a beneficial effect due to the addition of specific
components if there is a lack of one micro- or macronutrient
in the body. They may not have any proven pharmacologi-
cal effect [36].
Probiotics and prebiotics are live bacteria generally used
to help gastrointestinal conditions and specialized plant
fibres that nourish the good bacteria already present in the
large bowel or colon (gut microbiota), respectively. Neither
has a specific effect on pathological health conditions, but
they can both be effective in helping good bacteria grow
[3]. It can be observed that this definition partially overlaps
with the food supplement definition, creating confusing
information.
Medicinal products are well-defined for specific indica-
tions. They must follow specific legislation on efficacy, safety,
production and use in therapy to be authorized and
marketed. The dose and mechanism of action must be
identified in detail, as must possible undesired side effects
and pharmacokinetics depending on the dose and on the
method of administration. Each step is clearly designed and
addressed before a new drug can be considered for themarket.
Once a medicinal product is placed on the market, its
benefit/risk ratio continues to be assessed throughout its
entire lifespan.
The question is, why do nutraceuticals not follow a
similar procedure for assessing their safety, mechanism of
action and efficacy before and after they are marketed?
Nutraceuticals contain many active substances extracted
from a vegetal matrix (as a phytocomplex) or from animal
origin that are concentrated and administered in suitable
pharmaceutical form, and as per their definition, they must
have a proven pharmacological effect and rationale to be used
in a pathological condition (in addition to their nutritional
value), unlike food supplements and other food-derived
substances, including herbal derivatives.
The adoption of nutraceuticals in daily diets may help
prevent the onset of pathological conditions by possibly
delaying or avoiding the need to use pharmaceuticals in
subjects who qualify for an alternative, nonpharmacological
approach to a health condition.
The starting point for identifying and testing a nutraceu-
tical should be making a proper therapeutic hypothesis, such
as hypothesis that is coherent and supportable in the modu-
lation of a target capable of producing a beneficial health
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therapeutic effect. The specific target must then be defined
with all the available scientific data.
Each step must be identified and properly considered, and
know-how, experience and expertise are considered essential
to reach the target.
The first step to assess therapeutic efficacy should be
based on positive evidence from clinical data. This step
should include the contribution of different professionals
and different expertise, ranging from food chemistry and
food safety to structure–activity studies, with the aim of
assessing the mechanism of action, nutritional aspects,
pharmacology, pharmacokinetics and pharmacodynamics
of each nutraceutical.
The utmost importance of the clinical aspects of any study
concerning nutraceuticals as pharma-foods (e.g. in vivo
clinical trials) or any possible interactions between food
and/or drugs assumed together with nutraceuticals is not to
be underestimated [9, 37]. Medical doctor involvement in
these studies is a crucial step for proper evaluation of both
safety and efficacy assessment.
Figure 1 outlines the differences between food supple-
ments and nutraceuticals, stressing the efficacy/safety
requirements for these products. Figure 2 outlines a proposed
scheme that describes the necessary steps to consider when
identifying and developing a new nutraceutical.
It should be noted that the necessary time to develop a
new nutraceutical is reduced compared to time required to
develop a new drug, considering the natural origin of the
constituents of a nutraceutical and that a nutraceutical is
formed by many natural substances (not by a single sub-
stance, as in a drug).
Priority steps are indicated. The first step of utmost
importance is the identification of the heath condition to
address, followed by an assessment of safety and efficacy with
clinical trials and a complete and accurate study/assessment
of the mechanism of action. The absence of unwanted side
effects and efficacy are crucial steps prior to submitting an
application to EFSA in Europe (or to the equivalent authority
in other countries) for a health claim to be authorized and
advertised on the product label before advertising the prod-
uct or putting it on the market.
The nutritional claims permitted according to the
European legislation for food are defined and listed in the
Annex of Regulation (EC) No. 1924/2006, which was
ultimately amended by European Regulation (EU) No.
1047/2012. The health claims for food supplements refer to
the nutrient, food or food category or substance, address the
conditions of use and restrictions, and describe the health
relationship (EU Register of health claims). The admitted
claims are generally indicated as helps to ordevelop or stimulate
a beneficial effect, and they often refer to substances or pre- or
probiotics, not to a phytocomplex itself, as promoting a
beneficial health effect [20, 38].
In contrast, a completely different scenario exists for food
supplements (concentrated sources of nutrients or other
substances) added to a normal diet that can have a nutritional
or physiological effect. Directive 2002/46/EC proposed
harmonized rules on these products with the aim of
protecting consumers against potential health risks and
avoiding misleading information [17]. With respect to the
safety of food supplements, the Directive lays down a harmo-
nized list of vitamins and minerals that may be added for
nutritional purposes in food supplements (in Annex I of the
Directive), whereas Annex II of the same Directive contains
a list of permitted sources from which the vitamins and
minerals can be manufactured.
Figure 1
Differences between food supplements and nutraceuticals
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A different approach is needed to harmonize health
claims about nutraceuticals, which should be considered
a new category to recognize their potential as preventive
agents in some health conditions and to differentiate
them from food supplements. This approach, which is
based on scientific evidence substantiated by safety and
clinical efficacy tests, follows a step-by-step pathway as
outlined in Figure 2.
A proposal for a regulatory framework
for nutraceuticals
All the above-mentioned food-derived products are consid-
ered generally safe; however, in Japan, functional foods are
defined according to their use of natural ingredients, whereas
in the United States, they can also contain ingredients pro-
duced with biotechnology [39]. One possible source of con-
fusing information could be administration of the
pharmaceutical form – pills, tablets and capsules – which
can be the same for food supplements and nutraceuticals.
However, while nutraceuticals, in our opinion, should
have proven clinical efficacy, beneficial health effects, greater
or improved bioavailability and safety beyond their nutri-
tional value, all the other abovementioned food-derived
products may not need to have a specific effect on any health
condition substantiated by clinical trials.
The lack of a shared legislation is big challenge for nutra-
ceutical globalization because the existence of different regu-
lations can generate confusion and also give a somewhat
dissimilar definition of products that are present in different
countries.
Active substances, which can either be extracted from
plants as phytocomplexes or can be of animal origin, can cre-
ate a very promising nutraceutical toolbox that is useful for
promoting health, preventing disease, or offering general me-
dicinal properties, given their proven clinical efficacy when
they are concentrated and administered in a suitable pharma-
ceutical form [4]. This category encompasses food supple-
ments, vitamin- and/or mineral-based formulations, herbal
supplements, and animal origin products.
The main focus on food supplement legislation has thus
far addressed their safety and labelling, whereas less emphasis
has been given to product claims and intended use of these
supplements than for pharmaceuticals. This last aspect
is accomplished through good manufacturing practice
regulations, which should also be enforced. The terms
nutraceuticals and food supplements are often used without
noting the difference between them [40, 41].
A clear and shared regulation system allowing the identi-
fication and classification of these products at an interna-
tional level that clearly indicates requirements for quality,
efficacy, mechanism of action and safety could benefit poten-
tial consumers as well as the industry. Obtaining health
claims approval could also represent a growing challenge for
stakeholders because nutraceuticals are currently in a grey
area between pharmaceuticals and medicinal food.
Nonetheless, while the current European regulations (see
EC Regulation No. 1924/2006 of the European Parliament
and of the Council, recently updated by EU Regulation
2015/2283) define food categories and include a definition
Figure 2
The necessary steps to consider when developing a new nutraceutical
A. Santini et al.
666 Br J Clin Pharmacol (2018) 84 659–672
of food supplements, they do not officially mention or recog-
nize the term nutraceutical [20, 32].
According to this vision, the EFSA does not make any dis-
tinction between food supplements and nutraceuticals for
beneficial health claim applications for new products. Any
claim authorization is strongly conditioned by the availabil-
ity of clinical data in order substantiate its efficacy. In a simi-
lar way, the Dietary Supplement Health and Education Act
(DSHEA, 1994) defined dietary supplements as a category of
food, as did the US Food and Drug Administration (FDA),
which regulates dietary supplements with updates according
to the Food, Drug and Cosmetic Act (FD&C Act, 2014) per
Section 413 (d) of the FD&C Act, 21 U.S.C. 350b (d) [42, 43].
Regulatory rules in different countries
The milestone for assessing the safety and use of food was set
by the United Nations Food and Agricultural Organization
(FAO) and the World Health Organization (WHO) in the
Codex Alimentarius (FAO/WHO1992). This collection of docu-
ments contains general internationally recognized guidelines
that establish rules for producing and marketing foodstuffs
and their derivatives. Many countries use these guidelines,
which define health claims in terms of: (i) nutrient function;
(ii) enhanced function; and (iii) reduction of risk [44, 45].
Specifically, the nutrient function claim, which is defined
as “the claim that describes the physiological role of the nu-
trient in growth, development, and the normal function of
the body”, does not explicitly refer to beneficial health effects
of a nutrient or of a combination of micronutrients [44]. It
can be observed that nutraceutical (e.g. phytocomplexes)
and food supplement (e.g. combinations of micronutrients)
regulatory systems seem to evolve very slowly compared to
the growing number of products that are available on the
market worldwide.
In the USA, the FDA, which focuses on safety aspects and
food supplements, acknowledges the term nutraceutical and
applies a different set of regulations to them than those of
conventional foods and drugs. As per the Dietary Supplement
Health and Education Act established in 1994 (DSHEA), it is
the manufacturer’s responsibility to ensure that a nutraceuti-
cal is safe before it is marketed. The Food and Drug Adminis-
tration Modernization Act of 1997 contains sections that
enable health claims and nutrient content claims on food la-
belling to be authorized based on an authoritative statement
from the Academy of Sciences or other federal authorities
after notifying the FDA at least four months before the
introduction of the supplement on the market [42].
While the FDA is authorized to act against any unsafe
product on the market, the EFSA does not have the same
mandate. EFSA must authorize/approve in detail any health
claim before it is considered at a national or European level
prior to being put on the market following a specific request
from Member States, European Parliament or stakeholders.
Following the EFSA opinion, each State can decide indepen-
dently to set specific approval regulations and/or authoriza-
tion. In the USA, however, manufacturers and other
stakeholders do not have to register their products with the
FDA because there is no need to obtain FDA approval and/or
authorization before producing or selling food supplements
or nutraceuticals. Surveillance activity is relegated to govern-
mental agencies, and manufacturers are responsible for
ensuring that information reported on the product label is
true and not misleading [46]. In Canada, nutraceuticals are
regulated more like a drug than as a food category [47].
Other countries have specific legislation; for example In-
dian legislation does not ascribe any specific legal status to
nutraceuticals. The government of India established the Food
Safety and Standards Act (FSSA) in 2006 to introduce a
legislation system. FSSA does not separate functional foods,
nutraceuticals, and dietary supplements; instead, each is
indicated as food for a special dietary application. It considers
products with beneficial health claims to be similar to food
without any statements about nutraceuticals with clinical
trial results. In 2015, India notified the World Trade Organi-
zation of a draft regulation for nutraceuticals and foods for
special diets and medical purposes. The draft regulation
defined these categories based on ingredients, labelling,
additives, contaminants, and health and nutritional claims.
The draft regulation also determined the criteria for the
manufacturing and sale of these categories of foods and
recommended doses or consumption levels. The new
regulation, namely, Food Safety and Standards for Food for
Health Supplements, Nutraceuticals, Food for Special Dietary
Use, Food for Special Medical Purposes, Functional Food and
Normal Food Regulations 2016, is based on and framed from
Section 22 of the FSSA. The full text of the Regulation can
be accessed from the FSSA website (http://www.fssai.gov.in/),
and the Food Safety and Standard Act No. 34 2006 can be
accessed from the FSSA web portal (http://www.fssai.gov.in/
portals/0/pdf/food-act.pdf).
Japan, by contrast, was among the first countries to face
the issue of regulating food supplements and foodstuff by is-
suing the Foods for Specified Health Use (FOSHU) based on
a voluntary request from stakeholders for approval [48, 49].
This legislation, originally set in 1991, evolved into the
2003 Health Promotion Law [50].
Possible approval is available for food with beneficial
health activities even if these activities are not substantiated
with scientific evidence if the product meets the level of
FOSHU requirements (safety, nutritionally appropriate ingre-
dient content, etc.). Even food without an assessed and
defined mechanism of effectiveness for its function, namely,
qualified FOSHU and standardized FOSHU, can be consid-
ered. Any reduction of disease risk claim is allowed if the
reduction of disease risk is clinically and nutritionally
established in one ingredient.
In general, many countries, such as Australia or China,
regulate nutraceuticals simply as a category of food, and the
national regulations valid for food apply [51–54]. A simple
registration-based approach has been adopted by some
countries, such as Colombia, Brazil and Argentina [55]. A
notification-based approach addressed to the local compe-
tent authority is valid in Mexico and Chile. Nevertheless,
other countries, such as Brazil, China and Taiwan, have
stricter requirements, and prior to registration, a complete
animal or human clinical study is required [46]. Based on this
information, it is foreseeable that a safety assessment and
complete clinical study may be necessary before any nutra-
ceutical or any ingredient is put on the market. Moreover, a
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health claim should be authorized and attributed only after a
complete clinical study is proposed to the appropriate author-
ity for approval with the aim of substantiating its safety and
efficacy with respect to the claimed beneficial health effect
based on an understanding of the mechanism of action and
the absence of undesired side effects.
Dose and safety: the paradigm of red
yeast rice
Increases in cardiovascular disease have been further corre-
lated with improper dietary habits, leading to an increase in
morbidity and mortality and outlining the need for a differ-
ent approach to the management of hypercholesterolemia
to avoid the possible unwanted side effects of drugs, such as
widely used statins [13]. This aim has led to the use of red
yeast rice (RYR). RYR is a food obtained from fermentation
with the red yeast of Monascus purpureus, and the content of
its bioactive component monacolin K allowed it to be used
for people with moderate dyslipidaemia.
Monacolin K (chemically identical to lovastatin, a drug
used to control hypercholesterolaemia), which has been
recognized as a key component in cholesterol reduction,
has been validated as the source of its hypocholesterolaemic
effect. A recent study on the safety profile of RYR conducted
within the Italian Surveillance System of Natural Health
Products on possible unwanted side effects due to
consumption observed cases of myalgia and/or an increase
in creatine phosphokinase, liver injury and gastrointesti-
nal reactions, and, in some cases, hospitalization [56].
The potential outcomes of myopathies and liver injury
raise the hypothesis that the safety profile of RYR is similar
to that of statins [57, 58]. For this reason, accurate monitor-
ing of RYR and other food constituents should be promoted
to fully characterize their risk profile, thereby helping regula-
tory bodies take appropriate actions.
Another risk factor is represented by the possible presence
of secondary toxic metabolites, such as the mycotoxin
citrinin, whereas the variable statin content in different red
yeast rice-based food supplements generated a controversial
scenario in which dose inconsistency and co-occurrence of
the toxin citrinin resulted in criticism of its dietary supple-
mentation use [59].
Citrinin frequently contaminates foodstuff as do other
secondary metabolites produced by microfungi present in,
for example, milk [60]. Exposure to citrinin, produced by
microfungi of the Monascus species (Monascus purpureus
and Monascus ruber) and Penicillium species (Penicillium
citrinum, Penicillium expansum, Penicillium radicicola and
Penicillium verrucosum), can cause nephrotoxicity and a
strong oxidative stress [61]. The maximum level of this
contaminant has been determined by Regulation EU No.
519/2014 of the European Commission in March 2014,
which set the maximum acceptable level of citrinin as
2000 μg kg–1 in RYR food supplements [62].
The analysis of citrinin in RYR as a dietary supplement
and traditional medicine carried out using a citrinin
immuno-affinity column for sample clean-up before LC anal-
ysis with fluorescence detection enabled analysis of citrinin
with high degree of accuracy (limit of quantitation for citri-
nin in red yeast rice was 10 μg kg–1, and limit of detection
was 3 μg kg–1), which confirmed the presence of this contam-
inant in trace amounts [63].
A recent systematic analysis of 10 randomized controlled
trials involving 905 Chinese subjects with dyslipidaemia
compared the use of RYR (monacolin K) and simvastatin.
The results confirmed that they have similar effects on ele-
vated lipid levels, suggesting that the use of RYR as an alterna-
tive to simvastatin is not supported by current evidence,
excluding patients intolerant to statins [64].
The German Federal Institute for Drugs and Medical
Devices warned about the use of RYR, and the food safety
European regulation requirements for food supplements con-
taining active compounds established that the monacolin K
content should be considered a drug at levels higher than
5 mg day–1 due to existing scientific data supporting a phar-
macological effect at this dose [65]. This regulation differs
from the EFSA 2011 opinion in which the limit of monacolin
K from RYR was set at 10 mg day–1 for the maintenance of
normal blood levels of low density lipoprotein cholesterol
concentration [66].
This value has, however, been considered acceptable in
many European countries even though it has been observed
that lovastatin (monacolin K) can cause undesired side
effects, e.g. kidney problems or muscle issues; thus, RYR
products can also cause the same health issues, depending
on the dose and considering the higher bioavailability of
red yeast rice-based food supplements, as pure lovastatin
[67]. Recently, the Conseil Superior de la Sante of Belgium
advised that the exact amount of monacolin K in RYR is
highly variable, ranging from 3 to 30 mg daily depending
on the brand, representing a health risk due to the lack of
appropriate information to its users [68].
By contrast, the US FDA issued a warning on these RYR
products in 2007. According to this warning, the content of
monacolin K should be considered a drug at levels higher
than 5 mg day–1 due to existing scientific data that support
a pharmacological effect at this dose, as recently also con-
firmed by the German expert panel of the Bundesamt für
Verbraucherschutz und Lebensmittelsicherheit (BVL) und
das Bundesinstitut für Arzneimittel und Medizinprodukte
(BfArM) [65]. This report confirms the opinion of the Autorité
française de Sécurité sanitaire de l’Alimentation, de
l’Environnement et du Travail, which seems to suggest that
high values of monacolin K in RYR products should be
considered with caution due to possible monacolin K content
variability [69]. The possible contamination from co-
occurrence of the toxic metabolite citrinin generates an addi-
tional disputable scenario in which dose inconsistency and
safety issues suggest caution against the use and need for
shared regulation assessment to guarantee safety, content
and dose-related efficacy. The establishment of a regulatory
framework would help avoid this scenario. Innovative,
cross-sectorial strategies may contribute directly or indirectly
to improving the quality of life making our health and social
care systems more efficient and sustainable. Adherence to
adequate lifestyles and behaviour is important to improve
quality of life and prevent adverse health outcomes [70].
Multitude of good practices developed throughout
the European Union favours a comprehensive and
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multidimensional scaling-up strategy at European level. For
this reason, would be important to identify strategies to
implement a scale-up and to develop synergies [71].
Conclusion
Based on the above discussion, in our personal opinion, a
restructuring of the entire regulatory framework of dietary
supplements in view of the role of nutraceuticals is
deemed necessary to first give credit to their different
purposes and definition, and second, to assess their spe-
cific role in the prevention and treatment of pathological
conditions, supporting their potential medical use in pre-
vention and therapy only when proven by sound scientific
and clinical data.
The specificity of nutraceuticals would need a premarket
approval system substantiated by scientific data (in vivo
clinical trials) showing their complete safety and efficacy pro-
file. The regulatory approach could be based on the one
adopted for drugs, which is stricter and more complex. The
likelihood of this occurring in the foreseeable future is unfor-
tunately quite low. However, some measures could result in
improvements of the existing situation.
It may be reasonable for national competent authorities
to ask manufacturers to provide data on the safety, efficacy
and mechanism of action supporting any claims contained
on the labels of their products, especially when the term
nutraceutical is used.
Strict guidelines would be needed and shared at interna-
tional level to ensure that proper information is used to
substantiate any health claims on the product label and
detailed in the recommendation/safety guidelines, which
should be included in the packaged products.
Moreover, relevant information and data should be
related to the complex of substances forming a nutraceutical
and should not refer to a single substance (or a mixture of
different substances) of natural origin with physiological
activity and/or beneficial health effects, highlighting the
difference between food supplements and nutraceuticals.
It is indeed obvious that the current situation regarding
nutraceuticals is far from satisfactory; our aim is to stimulate
a fruitful debate on this subject. We hope that our proposals
generate comments and useful objections from other experts
in this field. This manuscript could be a starting point for a
discussion on these products, even if DeFelice has decided
to take a step backwards on his original classification of
nutraceutical products. Based on this decision, we still sug-
gest adopting a global approach to rethink a new/amended
regulatory framework.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharmaco-
logy.org, the common portal for data from the IUPHAR/BPS
Guide to PHARMACOLOGY [72], and are permanently
archived in the Concise Guide to PHARMACOLOGY
2017/18 [73].
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